Last reviewed · How we verify
PCV24 formulation 1
At a glance
| Generic name | PCV24 formulation 1 |
|---|---|
| Also known as | 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine |
| Sponsor | Shanghai Reinovax Biologics Co.,LTD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (EARLY_PHASE1)
- Clinical Trial of PCV24 in Adults (PHASE1)
- Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV24 formulation 1 CI brief — competitive landscape report
- PCV24 formulation 1 updates RSS · CI watch RSS
- Shanghai Reinovax Biologics Co.,LTD portfolio CI